Anjalee Khemlani

Health insurance stocks remain under pressure after the shooting of UnitedHealthcare executive Brian Thompson last week. Oscar Health CEO and former Aetna CEO Mark Bertolini reacts.

President-elect Donald Trump's nominees for the country's top health agencies and his previous track record in office have sparked concerns globally about a potential rise in "anti-science" views and the defunding of global public health efforts.

Allurion joins the pack to offer compounded GLP-1 access for patients.

Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.

President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the US Health and Human Services Department. Vaccine stocks slid on the news.

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.

Novavax sees Sanofi deal as path forward for company into profitability.

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

Eli Lilly's stock valuation sank by $100 billion Wednesday morning after the pharma giant reported third quarter earnings.